A Single-center, Randomized, Open-label, Two-arm Study to Evaluate the Ovarian Function Inhibition of a Monophasic Combined Oral Contraceptive (COC) Containing 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP) and a Monophasic COC Containing 20mcg Ethinylestradiol (EE)/3 mg DRSP (YAZ), Administered Orally Once Daily in a 24/4 Day Regimen for Three Consecutive Cycles
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2018
At a glance
- Drugs Estelledrospirenone/estetrol (Primary)
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Estetra S.A.
- 22 Jun 2018 Status changed from active, no longer recruiting to completed.
- 28 Mar 2018 Planned End Date changed from 31 Mar 2018 to 8 Jun 2018.
- 28 Mar 2018 Planned primary completion date changed from 31 Jan 2018 to 8 Jun 2018.